18805 COX AVENUE SUITE 250, SARATOGA, CA
Announces FDA Clearance of AI Highlights for CapsoCam Plus®
CapsoVision, Inc. Enters into Securities Purchase Agreement for 3.16M Shares
CapsoVision Enters $100 Million Controlled Equity Offering Agreement
Reports Second Quarter 2026 Financial Results
Appoints Gastroenterology Leader David S. Shields, M.D., to Board of Directors
Shareholder votes
Reports First Quarter 2026 Financial Results
Announces $14 Million Private Placement Financing
Q2
Q1
FY 2025
Q3
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
S-1
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Amended Statement of Changes in Beneficial Ownership
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Free Writing Prospectus
Amended Form D Notice of Exempt Offering of Securities